There is also a possibility that the gastric cancer patients with high expression of drug resistance proteins might experience greater survival benefit from adjuvant chemotherapy compared to patients with low expression as shown in other studies that investigated the expression of TS in rectal cancer and breast cancer (Johnston et al, 1994; Pestalozzi et al, 1997). This evidence concerns the gene PROS1 and gastric cancer.